Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mirum Pharmaceuticals (MIRM) Cash & Current Investments: 2020-2024

Historic Cash & Current Investments for Mirum Pharmaceuticals (MIRM) over the last 5 years, with Dec 2024 value amounting to $280.3 million.

  • Mirum Pharmaceuticals' Cash & Current Investments rose 32.03% to $375.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.2 billion, marking a year-over-year increase of 7.47%. This contributed to the annual value of $280.3 million for FY2024, which is 2.10% down from last year.
  • As of FY2024, Mirum Pharmaceuticals' Cash & Current Investments stood at $280.3 million, which was down 2.10% from $286.3 million recorded in FY2023.
  • Mirum Pharmaceuticals' 5-year Cash & Current Investments high stood at $286.3 million for FY2023, and its period low was $231.8 million during FY2020.
  • Moreover, its 3-year median value for Cash & Current Investments was $280.3 million (2024), whereas its average is $272.8 million.
  • In the last 5 years, Mirum Pharmaceuticals' Cash & Current Investments grew by 13.75% in 2023 and then dropped by 2.10% in 2024.
  • Yearly analysis of 5 years shows Mirum Pharmaceuticals' Cash & Current Investments stood at $231.8 million in 2020, then grew by 10.66% to $256.5 million in 2021, then fell by 1.88% to $251.7 million in 2022, then increased by 13.75% to $286.3 million in 2023, then dropped by 2.10% to $280.3 million in 2024.